Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
BackgroundHER2-positive breast cancer (BC) is highly aggressive with a poor prognosis. It is driven by HER2 oncoprotein activation/crosstalk with other receptors like EGFR/(HER1), HER3, and HER4, in addition to IGF-1R, making these receptors ideal therapeutic targets as they are expressed/overexpres...
محفوظ في:
| المؤلف الرئيسي: | Kheraldine, Hadeel (author) |
|---|---|
| مؤلفون آخرون: | Hassan, Arij Fouzat (author), Saeed, Sumayyah (author), Merhi, Maysaloun (author), Mateo, Jericha Miles (author), Ulamec, Monika (author), Peric-Balja, Melita (author), Vranic, Semir (author), Al-Thawadi, Hamda (author), Moustafa, Ala-Eddin Al (author) |
| التنسيق: | article |
| منشور في: |
2025
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1016/j.biopha.2025.118034 https://www.sciencedirect.com/science/article/pii/S0753332225002288 http://hdl.handle.net/10576/65155 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
حسب: Sara S Bashraheel (17807612)
منشور في: (2023) -
Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways
حسب: Hadeel, Kheraldine
منشور في: (2021) -
Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways
حسب: Hadeel Kheraldine (14231609)
منشور في: (2021) -
Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways
حسب: Hadeel Kheraldine (14231609)
منشور في: (2024) -
Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
حسب: Rasha M. Sareyeldin (18131371)
منشور في: (2019)